SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Commercial Services

Read more breaking news

 

 
News in brief

Pfizer signs up Biologics Inc as cancer drug distributor

13-Feb-2012
Last updated on 13-Feb-2012 at 09:04 GMT

US-based oncology services firm Biologics Inc will distribute a kidney cancer drugs being under a new contract with Pfizer.

The agreement – financial terms of which were not made public – covers the distribution of Pfizer’s renal cell carcinoma treatment Inlyta (axitinib), which was approved by the US Food and Drug Administration (FDA) late last month.

Stuart Frantz, CEO of Cary, North Carolina-based Biologics Inc, said: “It’s an honour to be selected as a Limited Distribution Network partner for Pfizer’s Inlyta,” adding that “We are committed to delivering the highest standard of care to patients and are excited to partner with Pfizer in providing another option to patients battling renal cell carcinoma.”

Pfizer joins top tier biopharmas like Genentech and AstraZeneca as users of Biologics’ cancer drugs distribution service.